Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetic dyslipidaemia.

D J Betteridge1

  • 1Royal Free and University College of Medical School, University College London, UK. j.betteridge@ucl.ac.uk

Diabetes, Obesity & Metabolism
|February 28, 2001
PubMed
Summary
This summary is machine-generated.

Patients with type 2 diabetes often have dyslipidaemia, characterized by high triglycerides and low HDL cholesterol. Lipid-lowering therapy is crucial for managing vascular risk in these individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).

Diabetic medicine : a journal of the British Diabetic Association·2013
Same author

Thiazolidinediones and fracture risk in patients with Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2011
Same author

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive.

Diabetes, obesity & metabolism·2011
Same author

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.

Diabetes, obesity & metabolism·2011
Same author

An Examination of Some Factors which Influence the Stability of in Vitro Platelet Responses.

Platelets·2010
Same author

Collagen-induced Platelet Activation In Vitro Increases Plasma Catecholamine Concentration.

Platelets·2010
Same journal

Efficacy and Safety of Ion Channel Modulators in Painful Diabetic Neuropathy.

Diabetes, obesity & metabolism·2026
Same journal

Exercise Resistance in Obese Male NZO Mice Manifests as Local Muscle Remodelling Without Glycaemic Improvements.

Diabetes, obesity & metabolism·2026
Same journal

GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.

Diabetes, obesity & metabolism·2026
Same journal

Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Diabetes, obesity & metabolism·2026
Same journal

A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.

Diabetes, obesity & metabolism·2026
Same journal

Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Diabetes, obesity & metabolism·2026
See all related articles

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Syndrome

Background:

  • Dyslipidaemia, marked by hypertriglyceridaemia and low HDL cholesterol, is a key feature of metabolic syndrome in type 2 diabetes.
  • These lipid abnormalities are linked to increased vascular risk, necessitating therapeutic interventions.
  • Insulin resistance is hypothesized as the underlying cause of dyslipidaemia in type 2 diabetes.

Purpose of the Study:

  • To explore the role of dyslipidaemia in type 2 diabetes and its management.
  • To evaluate the effectiveness of various interventions, including glycaemic control, lifestyle changes, and pharmacotherapy.
  • To discuss the current evidence and future directions for lipid management in diabetic patients.

Main Methods:

  • Review of existing literature and subgroup analyses from major clinical trials.

Related Experiment Videos

  • Discussion of the proposed link between insulin resistance and lipid abnormalities.
  • Examination of therapeutic strategies for dyslipidaemia in type 2 diabetes.

    • Main Results:

    • Dyslipidaemia significantly contributes to vascular risk in type 2 diabetes patients.
    • While glycaemic control and lifestyle modifications are important, they often fail to normalize lipid levels.
    • Subgroup analyses indicate that lipid-lowering therapy reduces coronary heart disease (CHD) risk in diabetic populations.

    Conclusions:

    • Aggressive lipid-lowering pharmacotherapy is warranted for type 2 diabetes patients with established CHD or high risk.
    • Ongoing trials specifically in diabetic populations are crucial for further evidence.
    • It is anticipated that most type 2 diabetes patients will eventually be prescribed lipid-lowering drugs.